11C T 2310
Alternative Names: [11C] T-2310; T-2310Latest Information Update: 28 Feb 2023
At a glance
- Originator Tetra Therapeutics
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis, In volunteers) in USA
- 10 Jan 2022 Tetra Discovery Partners withdraws a phase I trial in Alzheimers disease (In volunteers, Diagnosis) in USA due to change in research direction (NCT04044781)
- 10 Jan 2020 Phase-I clinical trials in Alzheimer's disease (Diagnosis, In volunteers) in USA (unspecified route) (NCT04044781)